Aconitine Poisoning — Comprehensive Disease Characteristics Research Report

1. Disease Information

Overview. Aconitine poisoning (aconite poisoning, monkshood/wolfsbane poisoning) is an acute toxidrome caused by ingestion, and less commonly cutaneous/mucosal absorption, of aconitine and related C19-diterpenoid alkaloids (mesaconitine, hypaconitine, jesaconitine, yunaconitine) found in Aconitum species (Ranunculaceae; monkshood, wolfsbane; Chinese: Fuzi/Chuanwu/Caowu). It is a toxin-mediated, non-genetic (environmental/toxicological) disease characterized predominantly by neurologic, gastrointestinal, and life-threatening cardiovascular (arrhythmic) manifestations resulting from persistent activation of voltage-gated sodium channels (Chan, Clin Toxicol 2009, PMID:19514874; Zhou et al., Forensic Sci Res 2020, PMC7241456).

Key identifiers. - ICD-10-CM: T46.991–T46.996 series is used for aconitine as a cardiotoxic agent poisoning in some coding schemes; general plant-toxin poisoning may also be coded under T62.2 (other noxious substances eaten as food, poisonous plants) depending on the jurisdiction's coding convention. - MeSH: "Aconitine" (chemical, D000109); "Aconitum" (plant genus, D000110); "Plant Poisoning" (D010942). - MONDO/OMIM/Orphanet: No dedicated disease-entity ID was identified — this is modeled as an environmental/toxic exposure syndrome rather than a classical nosological disease entity in these resources; curation as a dismech Environmental-category entry (parallel to Arsenic_Poisoning) is appropriate rather than as a genetic Disease. - CHEBI: aconitine, mesaconitine, hypaconitine, and jesaconitine each have dedicated CHEBI small-molecule entries (exact CURIEs should be confirmed via OAK/CHEBI lookup before curation).

Common synonyms: Aconite poisoning, monkshood poisoning, wolfsbane poisoning, Aconitum alkaloid toxicity, Fuzi poisoning, Chuanwu/Caowu poisoning, "bushi" poisoning (Japan).

Evidence basis: Information is derived almost entirely from aggregated case reports/case series (individual poisoning episodes reported in emergency medicine, toxicology, and forensic literature), a small number of retrospective cohort/registry analyses (e.g., mainland China 2004–2015 retrospective, Hong Kong incidence studies), and preclinical mechanistic studies in cell lines (H9c2 cardiomyocytes), zebrafish embryos, and rodents. There is no large prospective clinical trial base, consistent with an acute poisoning syndrome rather than a chronic disease.

2. Etiology

Disease causal factor: Direct environmental/toxicological — ingestion (occasionally topical/mucosal exposure) of aconitine or related Aconitum diterpenoid alkaloids. This is fundamentally a xenobiotic exposure, not a genetic or infectious disease.

Risk factors

Environmental/behavioral (dominant risk pathway): - Ingestion of improperly processed or raw Aconitum roots/tubers in traditional Chinese medicine (TCM) preparations (Fuzi, Chuanwu, Caowu) — inadequate boiling/steaming leaves toxic diester-diterpenoid alkaloid (DDA) content above safe thresholds (Frontiers 2026, toxicology/detox review). - Consumption of homemade medicinal liquor/wine steeped with Aconitum roots — a recurrent cause of clusters, e.g., the 2018 Chongqing, China outbreak reported by CDC MMWR (MMWR 71(16), 2022; PMC9042358). - Misidentification of Aconitum tubers as edible plants (e.g., confused with wild ginseng, horseradish, or other root vegetables) leading to accidental food poisoning. - Co-ingestion with ethanol, which potentiates aconitine-induced arrhythmogenesis ("ethanol-aconitine induced arrhythmia" is a specifically studied toxicological interaction; PMID:32250090). - Excessive dosing / self-medication with prepared aconite herbal formulas beyond recommended limits. - Intentional self-poisoning (suicide/self-harm) — reported cases exist in both Western and Asian settings (ScienceDirect, "Intentional ingestion of aconite: two cases of suicide"). - Geographic/cultural exposure: highest incidence in regions with active TCM, Ayurvedic, or Tibetan medicine use (mainland China, Hong Kong, Taiwan, Japan, Nepal, India), though sporadic cases occur worldwide from ornamental monkshood ingestion.

Pharmacogenetic/host factors (plausible but not directly clinically demonstrated): - Individual variation in CYP3A4/CYP3A5 and CYP2D6 activity — the principal enzymes metabolizing aconitine, mesaconitine, and hypaconitine via demethylation, N-deethylation, dehydrogenation, and hydroxylation (PMID:21277363). CYP2D6 is highly polymorphic (>130 star alleles; poor/intermediate/extensive/ultrarapid metabolizer phenotypes), and reduced-function alleles could plausibly prolong toxin exposure, though this has not been directly correlated with clinical poisoning severity in published human case series. - Elderly age is repeatedly cited as a poor-prognosis modifier due to diminished physiological (cardiac, renal, hepatic) reserve rather than a distinct susceptibility mechanism.

Protective factors - Adequate herbal processing (boiling/steaming Aconitum roots >2 hours) hydrolyzes the highly toxic C19-diester diterpenoid alkaloids to markedly less toxic monoester and non-ester derivatives, reducing total DDA content to <0.02% (200 μg/g) — the principal mitigation strategy used in TCM (Frontiers review, Lai et al. 2019). - Co-administration with Glycyrrhiza uralensis (licorice) in classical TCM formulas has been shown experimentally to promote CYP3A-mediated metabolism of Aconitum toxic components, attenuating toxicity (PMC9236245). - No genetic protective variant has been specifically characterized for aconitine toxicity.

Gene–environment interactions: The principal G×E axis is pharmacogenetic (CYP3A4/CYP2D6 metabolizer status) modulating the rate of clearance of an environmental toxin — i.e., a toxicokinetic rather than a toxicodynamic interaction. No genome-wide association or candidate-gene susceptibility study specific to aconitine poisoning was identified.

3. Phenotypes

Aconite poisoning classically produces a triad of neurologic, gastrointestinal, and cardiovascular manifestations, with onset typically within minutes to 2 hours (documented range 3 minutes to 6 hours) of ingestion (Chan 2009, PMID:19514874; Taiwan case series latent period 10–90 min). In a 17-patient Taiwan case series, neurologic features occurred in 17/17, cardiovascular in 14/17, gastrointestinal in 9/17, and other in 5/17 patients (Annals of Emergency Medicine, PMID:15111916).

Neurologic/sensory (early/hallmark signs): - Perioral/circumoral paresthesia and numbness — often the earliest, most characteristic symptom; suggested HPO: Paresthesia (HP:0003401) — verify a more specific perioral term. - Numbness/paresthesia of the extremities and tongue - Ataxia (HP:0001251) - Muscle weakness (HP:0001324), fasciculations - Seizures (HP:0001250) - Reduced consciousness / coma (HP:0001259)

Gastrointestinal: - Nausea (HP:0002018), vomiting (HP:0002013) - Abdominal pain (HP:0002027) - Diarrhea (HP:0002014) - Hypersalivation/sialorrhea

Cardiovascular (drives mortality): - Palpitations - Hypotension (HP:0002615), shock/cardiogenic shock - Bradycardia (HP:0001662) or sinus tachycardia — bidirectional autonomic effects reported - Ventricular ectopy, ventricular tachycardia (bidirectional VT is the classically described ECG hallmark), ventricular fibrillation, torsades de pointes (suggested HPO: Ventricular arrhythmia/Ventricular tachycardia — verify exact term, e.g., candidates near HP:0004308/HP:0011675) - Cardiac arrest (HP:0001695) - Refractory "electrical storm" in severe cases

Other: Sweating/diaphoresis, respiratory depression/failure (HP:0002878), hypothermia in some reports.

Phenotype characteristics: - Onset: Acute, minutes to hours post-exposure — this is uniformly an adult-onset acute presentation (age of "onset" reflects timing of exposure, not developmental stage), though pediatric accidental exposures are reported. - Severity: Highly variable — dose-dependent, ranging from mild paresthesia/GI upset to fulminant cardiogenic shock and death within hours. - Progression: Rapid, non-relapsing (single-exposure toxidrome); severity escalates over the first several hours if untreated, then resolves with toxin clearance/elimination (half-life estimates around several hours have been reported, though pharmacokinetic data in poisoned humans are limited and heterogeneous). - Frequency among affected individuals: Neurologic features are near-universal (~100% in case series); cardiovascular involvement occurs in a large minority to majority of symptomatic cases (e.g., 14/17, ~82%, in the Taiwan series); ventricular arrhythmias specifically occurred in ~4/17 (~24%) of that cohort.

Quality of life impact: No dedicated QoL instrument data exist for this acute toxidrome. Survivors of severe poisoning with cardiac arrest may have anoxic neurologic sequelae; most survivors of non-arrest presentations recover without long-term functional impairment, as the pathology is a reversible ion-channel-mediated electrophysiological/toxic insult rather than structural tissue destruction (absent secondary hypoxic-ischemic injury).

4. Genetic/Molecular Information

Aconitine poisoning is not a Mendelian/genetic disease — there are no causal or pathogenic germline variants. The molecular biology relevant to curation concerns (a) the pharmacological target and (b) metabolizing-enzyme pharmacogenetics:

Molecular target (not a "causal gene" but the toxin's binding target): - SCN5A (cardiac voltage-gated sodium channel Nav1.5, hgnc:10593) — principal cardiac target; aconitine binds neurotoxin receptor site 2 on the α-subunit, favoring the open channel state and causing persistent activation/blocking of inactivation, producing sustained Na⁺ influx (Zhou et al. 2020, PMC7241456; PMID:9430411). - Related neuronal/skeletal-muscle sodium channels (SCN1A–SCN4A family) mediate the neurologic and neuromuscular manifestations via the same site-2 mechanism on nerve and muscle membranes. - Structural work on the bacterial homolog NaChBac localizes an aconitine pore-blocking interaction to residue F224, and aconitine has also been shown to block peak current and shift activation of Nav1.7 (SCN9A) — relevant to the paresthesia phenotype. - Downstream, aconitine-induced Ca²⁺ overload in cardiomyocytes is mediated in part through TRPV2 (transient receptor potential cation channel subfamily V member 2) upregulation via p38 MAPK signaling, driving mitochondrial-pathway apoptosis (increased Bax/cleaved caspase-3, decreased Bcl-2) (Wang et al. 2021, ECAM, PMC8426055).

Metabolizing-enzyme genes (pharmacokinetic, not causal): - CYP3A4 (hgnc:2637) and CYP3A5 — primary hepatic metabolizers of aconitine, mesaconitine, and hypaconitine (Km/Vmax values reported per isoform; PMID:21277363, PMID:21550385). - CYP2D6 (hgnc:2625) — secondary contributor, highly polymorphic (poor/intermediate/extensive/ultrarapid metabolizer phenotypes). - CYP2C19, CYP2E1, CYP1A2 — minor contributing isoforms for hypaconitine and other congeners.

Pathogenic variants / allele frequency / somatic-vs-germline: Not applicable — no disease-causing germline or somatic variant is implicated. This distinguishes aconitine poisoning from congenital sodium-channelopathies (e.g., Brugada syndrome, Long QT type 3) that share the SCN5A target but arise from inherited gain-of-function/loss-of-function variants rather than exogenous toxin binding — a mechanistically relevant but etiologically distinct comparator (see cardiac_ion_channel_repolarization module in dismech's channelopathy modeling).

Epigenetic/chromosomal information: None reported; not applicable to this acute toxic exposure.

5. Environmental Information

Environmental factors (primary etiology, see §2): - Ingestion of raw or improperly processed Aconitum spp. tubers/roots (Fuzi, Chuanwu, Caowu; A. carmichaelii, A. kusnezoffii, A. napellus) - Homemade herbal/medicinal liquor or soup prepared with aconite roots - Contamination of other herbal products by aconite roots (misidentification during herb collection/processing) — see PMID:26481590 - Excessive or improperly dosed TCM/Ayurvedic/Tibetan medicine formulas containing prepared aconite - Suggested ECTO term category: exposure to plant alkaloid toxin via ingestion (specific ECTO CURIE for aconitine/Aconitum exposure should be verified via OAK before curation).

Lifestyle factors: - Concurrent ethanol consumption potentiates cardiotoxicity ("ethanol-aconitine induced arrhythmia," PMID:32250090) - Self-medication practices and use of unregulated/homemade herbal remedies without professional oversight - Occupational/recreational exposure is rare but reported for gardeners/horticulturists handling ornamental monkshood (cutaneous absorption)

Infectious agents: Not applicable — aconitine poisoning is a purely chemical/toxin-mediated disease with no infectious component.

6. Mechanism / Pathophysiology

Causal chain (initial trigger → clinical manifestation):

1. Ingestion/absorption of aconitine (and congeners mesaconitine, hypaconitine, jesaconitine) → rapid gastrointestinal or mucosal absorption, with symptom onset often within minutes given high lipid solubility and membrane permeability.
2. Binding to neurotoxin receptor site 2 on voltage-gated sodium channels (Nav1.5/SCN5A in cardiomyocytes; Nav1.7/SCN9A and other neuronal isoforms in peripheral nerves; skeletal-muscle Nav1.4) in the open channel state → the channel is locked into persistent activation and becomes refractory to normal inactivation.
3. Sustained Na⁺ influx at resting membrane potential → membrane depolarization, repetitive/ectopic action potential firing in nerve (paresthesia, numbness, seizures), skeletal muscle (weakness, fasciculation), and cardiac tissue.
4. Downstream cardiac electrophysiological consequences: sodium-channel-driven early and delayed afterdepolarizations (via secondary increases in intracellular Na⁺ and Ca²⁺), producing triggered activity and re-entrant substrate → ventricular ectopy, bidirectional ventricular tachycardia, ventricular fibrillation, and torsades de pointes.
5. Cellular/molecular amplification loop in cardiomyocytes: aconitine activates p38 MAPK signaling, which upregulates and promotes plasma-membrane trafficking of TRPV2, a calcium-permeable channel, causing sustained intracellular Ca²⁺ overload (PMC8426055; Hindawi ECAM 2021).
6. Mitochondrial dysfunction and oxidative stress: Ca²⁺ overload and direct mitochondrial injury increase reactive oxygen species (ROS) production, decrease PGC-1α expression and ATP content, and disrupt mitochondrial membrane potential.
7. Apoptotic and inflammatory amplification: increased pro-apoptotic Bax and cleaved caspase-3, decreased anti-apoptotic Bcl-2, and activation of the NLRP3/ASC/caspase-1 inflammasome axis drive cardiomyocyte apoptosis and inflammation, compounding the primary electrophysiological insult.
8. Clinical endpoint: refractory ventricular arrhythmias and/or cardiogenic shock/cardiac arrest — the principal cause of death in severe poisoning; concurrently, GI (direct mucosal irritant/vagal effects) and neuromuscular (peripheral nerve/muscle Na⁺-channel) manifestations occur in parallel, largely upstream-independent of the cardiac cascade.

Upstream vs. downstream: The sodium-channel binding event (step 2) is the shared upstream trigger for all three organ-system manifestations (neuro, GI/autonomic, cardiac); the TRPV2/p38 MAPK/Ca²⁺-overload/apoptosis axis (steps 5–7) is a cardiomyocyte-specific downstream amplifier distinct from the primary electrophysiological (arrhythmogenic) mechanism, i.e., this maps to two parallel but interacting node types: an acute electrophysiological node (arrhythmia, minutes-scale) and a slower cytotoxic/apoptotic node (myocardial injury, hours-scale).

Cell types involved: cardiomyocytes (CL:0000746), peripheral sensory/motor neurons (CL:0000540), skeletal muscle cells (CL:0000188/CL:0000187), gastrointestinal epithelial/enteric neuronal elements (indirect, vagally mediated).

Biological processes / suggested GO terms: - Voltage-gated sodium channel activity (GO:0005248; cardiac-specific GO:0086006) - Cardiac muscle cell action potential (GO:0086001) / regulation of heart rate by cardiac conduction (GO:0086091) - p38MAPK cascade (GO:0038066) - Calcium ion transmembrane transport (GO:0070588) - Reactive oxygen species metabolic process (GO:0072593) - Apoptotic process (GO:0006915); intrinsic apoptotic signaling pathway (GO:0097193) - NLRP3 inflammasome complex assembly (GO:0140639, verify)

Protein dysfunction: Not a loss/gain-of-function mutation but a pharmacological gain-of-function-like state induced by toxin binding — the channel protein is structurally normal but functionally "trapped open" by the alkaloid ligand (mechanistically analogous to, but distinct from, congenital SCN5A gain-of-function long-QT type 3 mutations).

Metabolic changes: Hepatic CYP3A4/3A5/2D6-mediated Phase I biotransformation (demethylation, N-deethylation, dehydrogenation, hydroxylation) generates at least six identified metabolites of aconitine in human liver microsomes; metabolite toxicity is generally reduced relative to parent compound, making hepatic clearance a rate-limiting detoxification step.

Immune system involvement: Secondary/minor — cardiomyocyte NLRP3/ASC/caspase-3-mediated sterile inflammation contributes to myocardial injury but is not a primary immune-mediated disease mechanism.

Tissue damage mechanisms: Oxidative stress and mitochondrial dysfunction (cardiomyocytes); electromechanical dysfunction without primary structural necrosis in mild-to-moderate cases; secondary hypoxic-ischemic injury to brain/other organs may occur in cardiac-arrest survivors.

Molecular profiling / advanced technologies: Zebrafish embryo transcriptomic/functional studies implicate Nrf2-HO-1/JNK-Erk signaling in aconitine-induced developmental cardiotoxicity and oxidative stress (PMC8097150); H9c2 rat cardiomyoblast cell-line studies provide the TRPV2/p38 MAPK mechanistic data above. No human single-cell, spatial transcriptomic, or CRISPR screen data specific to aconitine poisoning were identified.

7. Anatomical Structures Affected

Organ level: - Primary: Heart (myocardium — UBERON:0000948) — arrhythmogenesis and cardiomyocyte injury; Peripheral nervous system (UBERON:0000010) — sensory/motor neuropathy-like symptoms; Gastrointestinal tract (UBERON:0001007) — direct irritant and autonomic effects. - Secondary: Central nervous system (UBERON:0001017) — seizures, coma (may reflect direct toxin CNS penetration and/or secondary hypoxic injury from cardiac arrest); Skeletal muscle (UBERON:0001630) — weakness, fasciculation; Kidney — secondary injury in shock states; Liver — site of metabolism, occasional hepatotoxicity reported in animal models. - Body systems: Cardiovascular, nervous (central + peripheral + autonomic), gastrointestinal, musculoskeletal, and (secondarily) respiratory systems.

Tissue/cell level: - Cardiac muscle tissue / cardiomyocytes (CL:0000746) - Peripheral sensory and motor neurons (CL:0000540 or more specific subtypes) - Skeletal muscle fibers (CL:0000188) - Vascular smooth muscle / endothelium (secondary, via hypotension/shock)

Subcellular level (GO Cellular Component): - Plasma membrane (GO:0005886) — site of Na⁺/Ca²⁺ channel toxin action - Mitochondrion (GO:0005739) — site of ROS generation, ATP depletion, apoptotic signaling - Sarcoplasmic reticulum (cardiomyocyte Ca²⁺ handling, indirect)

Localization: Systemic/multi-organ — not laterally restricted; cardiac conduction-system involvement (His-Purkinje system) has been specifically implicated in some ventricular tachycardia cases (Ni et al. 2025, Ann Noninvasive Electrocardiol).

8. Temporal Development

Onset: Acute — this is an adult (or occasionally pediatric, accidental) acute poisoning event, not a developmental-onset disease. Symptom onset after ingestion is reported as early as 3 minutes and as late as 6 hours, with most series citing a latent period of 10–90 minutes and majority of symptoms manifesting within 2 hours.

Progression: - Early phase (minutes–1 hour): perioral/extremity paresthesia, nausea/vomiting. - Escalation phase (1–several hours): progressive neuromuscular weakness, ataxia, hypotension, cardiac arrhythmias (the critical window for clinical deterioration and intervention). - Critical/peak phase: refractory ventricular arrhythmias, cardiogenic shock, cardiac arrest — typically within the first several hours to about 24 hours post-ingestion in fatal cases; in a veterinary context, "death usually occurs within 6 hours" of a lethal dose. - Recovery phase: With survival past the acute arrhythmic window and toxin clearance (hepatic metabolism + supportive/extracorporeal elimination), most patients recover without permanent sequelae over days.

Disease course pattern: Self-limited, single-exposure acute toxidrome (not relapsing-remitting or chronic) — unless re-exposure occurs (e.g., repeated dosing errors with prepared aconite formulas).

Disease duration: Acute and self-limited; hospitalization typically spans days for supportive/monitoring care; ECMO-supported cases may extend to 1–2+ weeks.

Remission patterns: Spontaneous resolution with toxin clearance and supportive/antiarrhythmic treatment in most survivors; no disease-modifying "cure" exists — management is entirely supportive/time-buying pending endogenous elimination.

Critical periods: The first few hours post-ingestion represent the critical intervention window (decontamination, early antiarrhythmic/hemoperfusion therapy, and — if arrhythmias become refractory — early initiation of VA-ECMO), as repeatedly emphasized across case reports (PMC10835702).

9. Inheritance and Population

Epidemiology: - Approximately 5,000 aconite poisoning incidents were reported across China, Germany, Japan, and other countries during 1993–2005, with most fatal poisonings occurring in China. - A retrospective analysis of mainland China case reports (2004–2015) identified 53 victims across 27 published case reports. - Hong Kong has published dedicated incidence studies of herb-induced aconitine poisoning (Chan TY, Drug Saf 2002; link) given its documented endemic TCM-related exposure. - Sporadic outbreaks/clusters are reported globally, including a homemade medicinal liquor cluster in Chongqing, China (2018) described by CDC's MMWR (MMWR 71(16), 2022), and case reports from Nepal, Bangladesh, and Western countries (typically involving ornamental monkshood or imported herbal products).

Inheritance pattern: Not applicable — this is not a heritable disease (no Mendelian inheritance, penetrance, expressivity, anticipation, mosaicism, or carrier-frequency concepts apply).

Population demographics: - Affected populations: Highest burden in East and South Asian populations with active use of TCM, Tibetan medicine, and Ayurveda (China, Hong Kong, Taiwan, Japan, Nepal, India); sporadic cases occur worldwide (Europe, North America) typically from ornamental Aconitum napellus or imported herbal remedies. - Geographic distribution: Endemic in regions with traditional herbal medicine practice; case clusters often geographically tied to a specific herbal product batch or local liquor preparation. - Sex ratio: Case series show relatively balanced sex distribution (e.g., 9 men/8 women in the Taiwan cohort), though ratios vary by cohort and exposure route. - Age distribution: Predominantly adults (reported cohort ranges e.g., 30–70 years); elderly patients carry disproportionately poor prognosis due to reduced physiological reserve.

10. Diagnostics

Clinical tests: - ECG monitoring is the central bedside diagnostic and risk-stratification tool — bidirectional ventricular tachycardia is considered a characteristic (though not pathognomonic) finding in aconitine poisoning; monitoring for ventricular ectopy, VT, VF, and torsades de pointes is essential. - Electrolyte panel (magnesium, potassium) — informs both diagnosis of arrhythmia risk and guides magnesium-based therapy. - Laboratory tests: No routine clinical (point-of-care) assay for aconitine exists; diagnosis is primarily clinical (history of herbal/plant exposure + characteristic symptom triad + ECG findings). - Biomarkers: None validated for clinical use; research-grade LC-MS/MS quantification is used in specialized/forensic settings.

Specialized/forensic testing: - LC-MS/MS quantification of aconitine, mesaconitine, hypaconitine, and jesaconitine in whole blood, serum, or urine — validated methods report linearity 1.25–40 ng/mL with detection limits of 0.3–0.5 ng/mL ([Meng et al., Forensic Toxicol, PMID cited via link]); other assays report LOD/LOQ of 0.1/0.5 ng/g in blood. - Fatal case postmortem series report blood aconitine concentrations spanning 2.3–86.2 μg/L (femoral blood), with detection also possible in gastric content, urine, and kidney tissue. - Toxicological history-taking (identifying the specific herbal product, liquor, or plant material ingested) is often essential for definitive diagnosis, given the absence of routine hospital-based assays.

Genetic testing: Not applicable — this is not a genetic disease; no genetic test is diagnostic.

Clinical criteria: No formal diagnostic-criteria consensus statement (e.g., DSM/ICD-style) exists; diagnosis relies on a combination of exposure history, characteristic symptom triad (neuro + GI + cardiac), and supportive ECG findings, per toxicology reviews (PMID:19514874, PMID:38613376).

Differential diagnosis: Other cardiotoxic plant/alkaloid poisonings (e.g., cardiac glycoside/digoxin toxicity, taxine/yew poisoning, local anesthetic systemic toxicity), other causes of bidirectional VT (severe digoxin toxicity, catecholaminergic polymorphic VT), and other causes of perioral paresthesia (hyperventilation, hypocalcemia, ciguatera/tetrodotoxin poisoning — note tetrodotoxin has an opposite sodium-channel mechanism, site 1 blockade vs. aconitine's site 2 activation, making the clinical distinction mechanistically instructive).

Screening: No population screening program exists (this is an acute exposure event, not a screenable heritable/chronic condition); prevention relies on regulatory control of raw aconite herb sale/processing (see §13).

11. Outcome/Prognosis

Mortality: Reported case-fatality rates vary substantially by study population and severity: an overall in-hospital mortality of ~5.5% has been cited for aconite poisoning broadly, while more severe/referred cohorts report much higher fatality — one retrospective analysis of 35 cases found 17 deaths (49%) — reflecting substantial referral/severity bias across published series. A dedicated forensic toxicology series identified 25 aconitine-induced deaths (2005–2023) in one jurisdiction (ScienceDirect).

Cause of death: Predominantly refractory ventricular arrhythmias (VT/VF, "electrical storm") and asystole/cardiac arrest; cardiogenic shock is the other principal proximate cause.

Morbidity/functional outcomes: Survivors of non-arrest presentations generally have full recovery without chronic sequelae, consistent with the reversible (non-structural) nature of the primary ion-channel-mediated pathology; survivors of cardiac arrest may sustain anoxic brain injury and other complications common to any resuscitated arrest.

Complications: Cardiogenic shock, multi-organ hypoperfusion injury (acute kidney injury, hepatic injury) in severe/prolonged shock states, and — rarely — mechanical circulatory support-related complications (bleeding, limb ischemia) in ECMO-treated patients.

Prognostic factors: - Dose/exposure magnitude — the poisonous dose has been cited as low as ~0.2 mg with a lethal dose in the range of 2–5 mg (and separately, an oral minimum lethal human dose of 1–2 mg and a "lowest lethal dose" of 28 mg/kg bodyweight reported in another source — figures vary across the literature and should be treated as approximate ranges pending consolidation from a systematic toxicology reference). - Time to treatment initiation — the first several hours represent the critical intervention window. - Age — elderly patients have disproportionately worse outcomes. - Early recognition of refractory arrhythmia and escalation to VA-ECMO — case reports consistently associate early ECMO initiation (before irreversible multi-organ injury) with survival in otherwise refractory cases (PMC10835702; WJCC 2024). - No specific antidote exists, which is repeatedly emphasized as a key driver of adverse outcomes in refractory cases.

12. Treatment

There is no specific antidote for aconitine poisoning; management is entirely supportive and time-buying, aimed at maintaining perfusion and cardiac rhythm until endogenous (hepatic CYP3A4/2D6-mediated) elimination occurs.

Decontamination: - Early activated charcoal administration (gastric decontamination) if presenting soon after ingestion. - Gastric lavage/emesis/catharsis reported historically, though evidence for efficacy is limited.

Extracorporeal elimination: - Charcoal hemoperfusion — used in patients with ventricular arrhythmias; some series report successful reversion to sinus rhythm during/after hemoperfusion, though direct evidence of alkaloid removal efficacy is limited (PMID unlisted; Annals of Emerg Med case series). - Continuous renal replacement therapy (CRRT) used adjunctively in multimodal regimens.

Antiarrhythmic pharmacotherapy (evidence largely from pooled case-report analysis — Fitzgerald et al., Clin Toxicol 2017, PMID:28421842): - Flecainide and amiodarone show the strongest association with return to sinus rhythm across pooled human case reports. - Lidocaine, mexiletine, procainamide, and electrical cardioversion are less consistently effective and are more often associated with arrhythmia persistence. - Magnesium sulfate — used both as electrolyte correction and reported in successful case reports of arrhythmia reversal / combination therapy for "aconitine-induced electrical storm" (PMC12573093). - Atropine for symptomatic bradycardia.

Advanced circulatory/mechanical support: - Prolonged cardiopulmonary resuscitation (CPR) and cardiopulmonary bypass are recommended as "time-buying" strategies in refractory cases pending toxin clearance. - VA-ECMO (veno-arterial extracorporeal membrane oxygenation) — repeatedly reported as life-saving in refractory ventricular arrhythmia/cardiogenic shock; multiple recent case reports (2023–2025) document successful outcomes with early ECMO initiation, sometimes combined with hemoperfusion. - Ventricular assist device support reported in at least one historical case (PMID:7892979).

Supportive care: - Continuous cardiac monitoring, hemodynamic support (vasopressors as needed), airway management/ventilatory support for respiratory depression, seizure management (benzodiazepines).

Experimental/investigational targets: TRPV2 has been proposed as a potential molecular target for future pharmacotherapy of aconitine-induced cardiomyocyte injury, based on preclinical (H9c2 cell) mechanistic data — not yet in clinical use.

Suggested NCIT terms for treatment annotation: Pharmacotherapy (NCIT:C15986; antiarrhythmic agents as therapeutic_agent), Supportive Care (NCIT:C15747); Hemoperfusion and ECMO/extracorporeal circulatory support procedure terms should be verified via NCIT lookup before curation (exact CURIEs not confirmed in this research pass).

13. Prevention

Primary prevention: - Proper herbal processing: boiling/steaming raw Aconitum roots for >2 hours hydrolyzes toxic C19-diester diterpenoid alkaloids to non-toxic/less-toxic derivatives, reducing total DDA content to <0.02% (200 μg/g) — the cornerstone of TCM safety practice. - Regulatory alkaloid-content limits: e.g., Korean regulatory authorities cap total alkaloid content (as benzoylaconine) at 0.33% by titration method in prepared aconite products. - Scheduling/controlled distribution: In India, Aconitum herbs are classified as Schedule E(1) poisons under the Drugs and Cosmetics Rules, restricting use to supervision by licensed Ayurvedic practitioners. - Public health messaging against self-preparation of homemade medicinal liquor/soup using raw aconite roots, and against consuming unregulated herbal products of uncertain provenance. - Avoidance of co-ingestion with alcohol, given documented potentiation of cardiotoxicity.

Secondary prevention (early detection): No population screening program exists; early clinical recognition of the neuro-GI-cardiac triad in a patient with a compatible exposure history is the operative "detection" strategy, supported by rapid access to ECG monitoring in emergency settings.

Tertiary prevention: Standardized emergency-department and ICU protocols for early antiarrhythmic therapy, hemoperfusion, and low-threshold escalation to VA-ECMO in refractory cases (see §12) function as tertiary prevention of death/major morbidity once poisoning has occurred.

Immunization: Not applicable (non-infectious toxin exposure).

Genetic counseling / genetic screening: Not applicable.

Public health interventions: Herbal-market regulation and quality control of TCM/Ayurvedic aconite-containing products; outbreak investigation and public communication following cluster events (e.g., CDC MMWR reporting of the 2018 Chongqing homemade liquor cluster) to prevent recurrence.

Environmental interventions: Regulation/labeling of ornamental monkshood sale in regions where accidental horticultural exposure has been reported; supervision of herb-collection practices to prevent inadvertent contamination of other medicinal herbs with aconite roots.

14. Other Species / Natural Disease

Taxonomy of the source organism: Aconitum spp. (family Ranunculaceae), notably A. napellus (monkshood, Europe/temperate regions), A. carmichaelii (Fuzi, China), A. kusnezoffii (Caowu, China) — plant NCBI Taxon IDs should be confirmed via lookup if curating the source organism (not the affected host species).

Species naturally affected by poisoning: - Livestock: Cattle and goats are most frequently affected by grazing on monkshood in pasture settings; horses are also susceptible (HorseDVM; CowDVM; PMC4690134). - Companion animals: Dogs are reported to be susceptible to monkshood ingestion (Pet Poison Helpline). - Clinical signs in animals parallel human poisoning: initial gastrointestinal distress (drooling, bloating, emesis) followed by musculoskeletal weakness, difficulty breathing, cardiac rhythm disturbances (bradyarrhythmia), and sudden death — death typically occurs within 6 hours of a lethal ingested dose in livestock, with cardiac effects (heart-rate slowing) often the proximate cause.

Comparative pathology: The core mechanism (voltage-gated sodium channel site-2 activation) is conserved across vertebrate species, given the high evolutionary conservation of the sodium channel pore and site-2 binding region — this underlies why rodent, zebrafish, and livestock/companion-animal poisoning all recapitulate the human neuro-cardiac toxidrome.

Veterinary relevance: Aconite/monkshood poisoning is a recognized cause of pastoral livestock loss in regions where the plant grows wild, and a recognized companion-animal (dog) poisoning risk from ornamental garden plantings; it is managed by the same supportive/antiarrhythmic principles as human poisoning, adapted to veterinary practice.

Zoonotic potential: Not applicable (a toxin exposure, not a transmissible infectious disease); no cross-species transmission risk beyond shared environmental exposure to the same toxic plant.

15. Model Organisms

Rodent models: - Mouse LD50 values: oral 1.8 mg/kg, intraperitoneal 0.31 mg/kg (also cited as 0.27 mg/kg i.p. in a second source), intravenous 0.12 mg/kg — the roughly 10-fold difference between oral and parenteral LD50 reflects substantial first-pass hepatic metabolism/reduced oral bioavailability. - Subacute mouse poisoning models have characterized hematological and histopathological effects of repeated low-dose aconitine exposure (Frontiers in Veterinary Science 2022). - Rat models have demonstrated direct embryotoxic effects during the organogenetic period, and rat studies of aconitine-induced Ca²⁺ overload/p38 MAPK-mediated apoptosis in vivo complement the H9c2 cell-line mechanistic data (ScienceDirect).

Zebrafish embryo models — an increasingly important developmental/cardiotoxicity screening platform: - Aconitine produces concentration-dependent embryo mortality, arrhythmias, extended sinus venosus–bulbus arteriosus distance, and pericardial edema. - Reported cardiotoxic thresholds: 2.5 μg/L aconitine and 20 μg/L mesaconitine caused deficient cardiovascular development with yolk-sac hemorrhage and early cardiac dysfunction at 96 hours post-fertilization. - Mechanistic zebrafish studies implicate the Nrf2-HO-1/JNK-Erk signaling axis in aconitine-induced developmental toxicity, oxidative stress, and ROS-mediated mitochondrial apoptosis (PMC8097150), and a related study links aconitine-induced cardiotoxicity to dysregulated calcium-signaling gene expression in zebrafish embryos (PMID:30639578). - Zebrafish models allow comparative cardiotoxicity ranking of different Aconitum diterpene alkaloids (aconitine, mesaconitine, hypaconitine, and others).

Cell-line (in vitro) models: - H9c2 rat cardiomyoblast cell line — the principal in vitro platform for dissecting the TRPV2/p38 MAPK/Ca²⁺-overload/apoptosis mechanism described in §6, and for testing candidate mitigating compounds.

Model characteristics — recapitulation and limitations: - Both rodent and zebrafish models faithfully recapitulate the core electrophysiological (arrhythmogenic) and cytotoxic (oxidative stress/apoptotic) arms of human aconitine cardiotoxicity, consistent with the high conservation of the sodium-channel target. - Zebrafish embryo models are particularly well suited to rapid, quantitative cardiotoxicity/developmental-toxicity screening but cannot model the full adult human clinical syndrome (e.g., adult conduction-system anatomy, His-Purkinje-specific arrhythmia mechanisms reported in some human case reports). - Livestock/companion-animal natural disease (rather than induced experimental model) provides real-world corroboration of the human toxidrome but is not a controlled research model system.

Research applications: These models are used to (a) rank comparative toxicity of different Aconitum alkaloid congeners, (b) dissect molecular mechanism (TRPV2, p38 MAPK, Nrf2-HO-1/JNK-Erk pathways), and (c) screen candidate therapeutic/mitigating compounds (e.g., co-administered herbal components such as Glycyrrhiza uralensis that promote CYP3A-mediated detoxification).

Model databases: No dedicated aconitine-poisoning-specific model registry exists; relevant strains/lines are accessed via standard model-organism resources (IMSR/MGI for mouse, ZFIN for zebrafish, and standard cell-line repositories such as ATCC/Cellosaurus for H9c2).

Summary of Suggested Ontology Terms (for dismech curation — verify all IDs via OAK before use)

Sources

• Aconite poisoning – Chan TY, Clin Toxicol (Phila) 2009 (PMID:19514874)
• Research Progress on the Molecular Mechanisms of Toxicology of Ethanol-Aconitine Induced Arrhythmia (PMID:32250090)
• Magnesium in Aconitine-Induced Electrical Storm — PMC12662806
• Aconitum sp. alkaloids: modulation of voltage-dependent Na+ channels (PMID:9430411)
• Bidirectional ventricular tachycardia resulting from herbal aconite poisoning — Ann Emerg Med
• Clinical features and management of herb-induced aconitine poisoning (PMID:15111916)
• Recurrent malignant ventricular arrhythmias and paresthesia — a case report — PMC10740282
• Ventricular Tachycardia Possibly Originated From the His-Purkinje System — aconitine poisoning, 2025
• Ventricular Tachycardia due to Overdose of Tibetan Drugs — PMC12117196
• The management of ventricular dysrhythmia in aconite poisoning (PMID:28421842)
• Aconite poisoning managed with a ventricular assist device (PMID:7892979)
• A Narrative Review of Aconite Poisoning and Management, 2024/2025 (PMID:38613376)
• Aconitum Alkaloid Poisoning Because of Contamination of Herbs by Aconite Roots (PMID:26481590)
• Research progress of aconitine toxicity and forensic analysis of aconitine poisoning — Forensic Sciences Research, PMC7241456
• Case reports of aconite poisoning in mainland China 2004–2015 — retrospective analysis
• Case report: Accidental aconitine poisoning from inappropriate use of Chinese patent medicine — PMC11754414
• Poisoning Associated with Consumption of a Homemade Medicinal Liquor — Chongqing, China, 2018, MMWR 71(16), 2022
• Incidence of Herb-Induced Aconitine Poisoning in Hong Kong — Drug Safety
• Combined blood purification and antiarrhythmic therapy for acute aconitine poisoning — PMC12482442
• Extracorporeal membrane oxygenation in cardiovascular medication poisoning — German-wide study — PMC11410930
• Treatment of aconitine poisoning using VA-ECMO — case report, WJCC 2024
• Severe aconite poisoning treated with VA-ECMO — PMC10835702
• ECMO combined with hemoperfusion for aconitine poisoning — 2025
• Involvement of CYP3A4/5 and CYP2D6 in the metabolism of aconitine (PMID:21277363)
• Microsomal CYP-mediated metabolism of hypaconitine (PMID:21550385)
• Glycyrrhiza uralensis promotes CYP3A metabolism of Aconitum toxic components — PMC9236245
• Simultaneous LC-MS-MS analysis of aconitine, mesaconitine, hypaconitine, jesaconitine in whole blood — Forensic Toxicology
• Determination of aconitine in body fluids by LC-MS-MS
• Aconitine Induces TRPV2-Mediated Ca2+ Influx via p38 MAPK, Promotes Cardiomyocyte Apoptosis — PMC8426055
• Aconitine-induced Ca2+ overload causes arrhythmia and triggers apoptosis via p38 MAPK in rats
• Processed lateral root of Aconitum carmichaelii: cardiotonic effects and cardiotoxicity mechanisms — Frontiers in Pharmacology
• Involvement of Nrf2-HO-1/JNK-Erk Signaling in Aconitine-Induced Developmental Toxicity in Zebrafish Embryos — PMC8097150
• Aconitum alkaloids induce cardiotoxicity in embryonic zebrafish via cardiovascular gene expression (PMID:30639578)
• Hematological and Histopathological Effects of Subacute Aconitine Poisoning in Mouse — Frontiers in Veterinary Science 2022
• Alkaloid-Containing Plants Poisonous to Cattle and Horses in Europe — PMC4690134
• Monkshood Poisoning in Cattle — CowDVM
• Monkshood Poisoning in Horses — HorseDVM
• Monkshood Is Toxic To Dogs — Pet Poison Helpline
• Quantification and Simplified Detoxification of Fuzi, Root of Aconitum carmichaelii
• The toxicology and detoxification of Aconitum: traditional and modern views — PMC8314510
• Toxicological investigation of 25 aconitine-induced deaths from 2005 to 2023
• Intentional ingestion of aconite: two cases of suicide

Reference Validation

Checked with linkml-reference-validator 0.2.1.

Quotes not found in the cited source

Searched the abstract, any retrieved full text, and the title. A quote drawn from a part of the paper that was not retrieved will appear here too, so check before treating one as invented:

Every one of these was searched against an abstract alone, with no full text retrieved - marked abstract only below. Where full text can be fetched, re-running with it will settle them; where the source publishes only a summary to PubMed, as GeneReviews chapters do, it will not, and the quote has to be checked by hand against the chapter itself.

• PMID:32250090 (abstract only): "ethanol-aconitine induced arrhythmia,"
• Text part not found as substring: 'ethanol-aconitine induced arrhythmia,' (note: only abstract available for PMID:32250090, full text may contain this excerpt)
• PMC:PMC12573093 (abstract only): "aconitine-induced electrical storm"
• Text part not found as substring: 'aconitine-induced electrical storm' (note: only abstract available for PMID:41165054, full text may contain this excerpt)